#J147 Alzheimer's

[wisepowder]

J147 Powder Benefits: A Potent Curcumin Derivative丨wisepowder

What Is J147 Powder?

J147 powder is different to the common seen nootropics powder for Alzheimer's disease,J147 powder is neither an acetylcholinesterase inhibitor nor a phosphodiesterase inhibitor, yet it enhances cognition with a short-term treatment.

 J147 Vs Curcumin

J147 is an experimental drug with reported effects against both Alzheimer's disease and ageing in mouse models of accelerated aging. What is the difference between J147 and Curcumin?

 J147 (CAD-031) is a Curcumin and Cyclohexyl-Bisphenol A (CBA) derivative that is a potent neurogenic and neuroprotective drug.

It was developed for the use of treating neurodegenerative conditions associated with aging.

 Curcumin is a polyphenol and the active component of Turmeric and Ginger. Curcumin has many proven benefits in treating numerous diseases, but due to its poor ability to cross the Blood-Brain Barrier (BB), there are clear limitations.

 J147 can cross the BBB into the brain (strong) and induce neuronal stem cell production.

 J147 Benefits

The benefits of J147 may include:

 1) Improves Mitochondrial Function And Longevity

2) Prevents Alzheimer's Disease

3) Improves Memory

4) Grows The Brain

5) Protects Neurons

6) May Improve Diabetes

7) Fights Pain And Neuropathy

8) May Improve Anxiety

 Buy J147 Powder online

 Many nootropics powder supplier sell J147 under the nootropic catalog, In order to gain the benefits of J147, you can buy J147 powder from the trustworthy nootropics powder factory. They can provide the testing reports of the goods.

[my-steroid-raw-powder]

Experimental Drug J147(1146963-51-0) Alzheimer’s Aging http://www.aasraw.com/experimental-drug-j147-alzheimers-aging/ http://www.aasraw.com/products/j-147-powder/ Alzheimer’s disease research has attracted some of the most brilliant minds in medical research over the past 20 years. While researchers have learned a lot about the diseases, its pathology, and its triggers, relatively little progress has been in made on fighting the disease. The team behind experimental drug J147 (1146963-51-0) decided to take a different approach. The early results have been impressive, and researchers are continuing to study how this new drug interacts with the different cells of the body. What is J147? J147 is a nootropics powder first developed in 2011. Researchers have found that the drug, across several different studies, can reverse memory loss and slow, or even reverse, Alzheimer’s in mice. J147 powder is a phenyl hydrazide. It is derived from the curry spice component curcumin. It is a low toxicity. Despite some early concerns, J147 powder has not been shown to be carcinogenic. Researchers tested extensively for this possibility by examining the metabolites of J147 in human and mouse microsomes and mouse plasma. The results showed that J147 is not metabolized to aromatic amines or hydrazines. #J147#J147powder#1146963510#Alzheimer#nootropicspowder#J147bebefits#J147dosage#J147sideeffects#J147powdersupplier#J147powderlab#

[amcrasto]

J-147

J-147

N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N’-[(E)-(3-methoxyphenyl)methylene]acetohydrazide

Molecular FormulaC18H17F3N2O2

Average mass350.335 Da

2,2,2-trifluoroacetic acid-1-(2,4-dimethylphenyl)-2-[(3-methoxyphenyl)methylene]hydrazide

Acetic acid, 2,2,2-trifluoro-, 1-(2,4-dimethylphenyl)-2-[(1E)-(3-methoxyphenyl)methylene]hydrazide

N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N’-[(E)-(3-methoxyph…

[vinodmeltoe-blog]

https://www.aasraw.com/experimental-drug-j147-alzheimers-aging/

Alzheimer's is at the forefront of biomedical research.Researchers are working to uncover Alzheimer's drug(AD drug) candidates: J147, CMS121, CAD31

[neurosciencenews]

Alzheimer’s drug candidates reverse broader aging

CMS121 and J147, two drug candidates that improve memory and slow neurodegeneration associated with Alzheimer’s disease, also slow aging in healthy, older mice. The compounds block damage to neurons caused by general aging and restore levels of specific molecules to those seen in younger animals.

[rainybouquetstrangerlove-blog]

What is Raw J-147 powder (1146963-51-0)?

https://www.phcoker.com/product/1146963-51-0/

J-147 is an experimental drug with reported effects against both Alzheimer's disease and ageing in mouse models of accelerated aging.It is a curcumin derivative and a potent neurogenic and neuroprotective drug candidate initially developed for the treatment of neurodegenerative conditions associated with aging that impacts many pathways implicated in the pathogenesis of diabetic neuropathy.

J-147 almost ready for clinical trials in humans. Now, Salk scientists have solved the puzzle of what, exactly, J147 does. In a paper published January 7, 2018, in the journal Aging Cell, they report that the drug binds to a protein found in mitochondria, the energy-generating powerhouses of cells. In turn, they showed, it makes aging cells, mice and flies appear more youthful....

[scifigeneration]

Alzheimer’s drug turns back clock in powerhouse of cell

The experimental drug J147 is something of a modern elixir of life; it's been shown to treat Alzheimer's disease and reverse aging in mice and is almost ready for clinical trials in humans. Now, Salk scientists have solved the puzzle of what, exactly, J147 does. In a paper published January 7, 2018, in the journal Aging Cell, they report that the drug binds to a protein found in mitochondria, the energy-generating powerhouses of cells. In turn, they showed, it makes aging cells, mice and flies appear more youthful.

"This really glues together everything we know about J147 in terms of the link between aging and Alzheimer's," says Dave Schubert, head of Salk's Cellular Neurobiology Laboratory and the senior author on the new paper. "Finding the target of J147 was also absolutely critical in terms of moving forward with clinical trials."

Schubert's group developed J147 in 2011, after screening for compounds from plants with an ability to reverse the cellular and molecular signs of aging in the brain. J147 is a modified version of a molecule found in the curry spice curcumin. In the years since, the researchers have shown that the compound reverses memory deficits, potentiates the production of new brain cells, and slows or reverses Alzheimer's progression in mice. However, they didn't know how J147 worked at the molecular level.

In the new work, led by Schubert and Salk Research Associate Josh Goldberg, the team used several approaches to home in on what J147 is doing. They identified the molecular target of J147 as a mitochondrial protein called ATP synthase that helps generate ATP-the cell's energy currency-within mitochondria. They showed that by manipulating its activity, they could protect neuronal cells from multiple toxicities associated with the aging brain. Moreover, ATP synthase has already been shown to control aging in C. elegans worms and flies.

"We know that age is the single greatest contributing factor to Alzheimer's, so it is not surprising that we found a drug target that's also been implicated in aging," says Goldberg, the paper's first author.

Further experiments revealed that modulating activity of ATP synthase with J147 changes the levels of a number of other molecules-including levels of ATP itself-and leads to healthier, more stable mitochondria throughout aging and in disease.

"I was very surprised when we started doing experiments with how big of an effect we saw," says Schubert. "We can give this to old mice and it really elicits profound changes to make these mice look younger at a cellular and molecular level."

The results, the researchers say, are not only encouraging for moving the drug forward as an Alzheimer's treatment, but also suggest that J147 may be useful in other age-associated diseases as well.

"People have always thought that you need separate drugs for Alzheimer's, Parkinson's and stroke" says Schubert. "But it may be that by targeting aging we can treat or slow down many pathological conditions that are old-age-associated."

The team is already performing additional studies on the molecules that are altered by J147's effect on the mitochondrial ATP synthase-which could themselves be new drug targets. J147 has completed the FDA-required toxicology testing in animals, and funds are being sought to initiate phase 1 clinical trials in humans.

Other researchers on the study were A. Currais, M. Prior, W. Fischer, C. Chiruta, D. Daugherty, R. Dargusch and P. Maher of the Salk Institute; E. Ratliff and K. Finley of San Diego State University; P.B. Esparza-Molto and J.M. Cuezva of the Universidad Autonoma de Madrid; and M. Petrascheck of The Scripps Research Institute.

The work and the researchers involved were supported by grants from the National Institutes of Health, California Institute of Regenerative Medicine, the Nomis Foundation, the Della Thome Foundation, the Bundy Foundation, the Hewitt Foundation, the Paul F. Glenn Center for Aging Research at the Salk Institute and the Waitt Foundation.

[raymondmccullers]

Alzheimer’s drug candidates reverse broader aging, study shows

In mouse models of Alzheimer’s disease, the investigational drug candidates known as CMS121 and J147 improve memory and slow the degeneration of brain cells. Now, researchers have shown how these compounds can also slow aging in healthy older mice, blocking the damage to brain cells that normally occurs during aging and restoring the levels of specific molecules to those seen in younger brains. Alzheimer’s drug candidates reverse broader aging, study shows syndicated from https://triviaqaweb.blogspot.com/

[windows-to-soul-blog]

Cure for Alzheimer's?

https://www.google.si/url?sa=t&rct=j&q=&esrc=s&source=web&cd=2&cad=rja&uact=8&ved=0ahUKEwiO2o6g-J7cAhWjDpoKHaTyBnkQFggvMAE&url=https%3A%2F%2Fmedicalxpress.com%2Fnews%2F2018-01-molecular-j147-nearing-clinical-trials.html&usg=AOvVaw2fjHXAxgtkfUxeplqAXamm

[wisepowder]

Alzheimer’s Disease: Etiology, Diagnosis And All Treatment Options

Alzheimer’s Disease: Etiology, Diagnosis And All Treatment Options

What is Alzheimer’s Disease? Alzheimer’s disease is one of the most common causes of disability in the aging population. It is a neurological disorder that progressively causes shrinkage of brain tissues and early neuronal degeneration. It is also the commonest form of dementia, resulting in dysfunctions in memory, social skills, thinking, and behavior. Globally, over 30 million people over age…

[azveille]

ALZHEIMER : Enfin l’espoir d’un médicament efficace ?

2 médicaments expérimentaux contre la maladie d'Alzheimer démontrent ici leur efficacité, à la fois contre le déclin cognitif dans la maladie d’Alzheimer, mais aussi, plus largement "contre" le vieillissement « normal » des cellules cérébrales. Cette équipe de scientifiques du Salk Institute (La Jolla) en apportent les premières preuves sur un modèle animal. De premiers résultats, présentés dans la revue eLife, qui apportent l’espoir de pouvoir ralentir les changements moléculaires, normaux et pathologiques, associés au vieillissement.

Car on l’oublie parfois, la vieillesse est le plus grand facteur de risque de la maladie d'Alzheimer : au-delà de 65 ans, le risque de développer la maladie double tous les 5 ans environ. Cependant, au niveau moléculaire, les scientifiques n’ont pas encore identifié les voies ou les processus associés au vieillissement qui contribuent à la maladie d'Alzheimer. « Cette contribution des processus préjudiciables associés à la vieillesse et à la maladie liée à l’âge, a été largement négligée dans la recherche de nouveaux médicaments contre la maladie d'Alzheimer », explique l’auteur principal, Antonio Currais, chercheur au Salk Institute.

2  candidats-médicaments  améliorent la  mémoire  et  ralentissent  la dégénérescence des cellules cérébrales

L’équipe a testé ces 2 molécules, « CMS121 » et « J147 » sur des modèles murins de la maladie d'Alzheimer et montre, sur la souris modèle, que ces composés peuvent non seulement inverser certains symptômes de la maladie d’Alzheimer mais aussi ralentir le vieillissement chez les souris âgées en bonne santé, en bloquant les dommages aux cellules du cerveau qui se produisent normalement au cours du vieillissement et en rétablissant les niveaux de molécules essentielles à ceux observés dans des cerveaux plus jeunes.

•   Au départ, l’équipe avait développé CMS121 et J147, des variantes de composés végétaux aux propriétés médicinales et avait montré leur capacité à maintenir les neurones en vie une fois exposés au stress cellulaire caractéristique de la maladie d'Alzheimer et du vieillissement.

•   Ensuite, les chercheurs ont testé les candidats médicaments sur des modèles animaux de la maladie d’Alzheimer. Ces expériences ont révélé comment fonctionnent ces composés et ont suggéré qu'ils ciblent des voies moléculaires déjà connues comme impliquées dans la longévité et le vieillissement.

•   Enfin, et c’est l’objectif de cette nouvelle étude, les chercheurs montrent sur des souris modèles de vieillissement accéléré que l'un des candidats-médicaments réduit le déclin cognitif et que les 2 candidats permettent de préserver l'expression des gènes associés aux mitochondries, en dépit du vieillissement.

Les  2  candidats  empêchent  les  changements  moléculaires  associés  au vieillissement : ainsi, l’étude apporte une première validation de l’efficacité de ces deux composés non seulement en tant que candidats-médicaments contre la maladie d'Alzheimer, mais également comme médicaments « anti-âge », résume Pamela Maher, chercheur au Salk et auteur-correspondant de l’étude. En effet, selon ces données, ces candidats médicaments ciblent une voie qui relie le vieillissement normal à la maladie d'Alzheimer et pourraient traiter, au-delà de la maladie d’Alzheimer, un large éventail de conditions. « L'essentiel, c'est que ces deux composés empêchent les changements moléculaires associés au vieillissement ».

Les 2 candidats protègent les m itochondries des cellules cérébrales en augmentant les niveaux d’une enzyme, l'acétyl-coenzyme A (acétyl-coA). Dans les cellules cérébrales isolées, lorsque les chercheurs bloquent une enzyme qui décompose normalement l'acétyl-CoA, ou lorsqu'ils ont ajouté des quantités supplémentaires d'un précurseur d'acétyl-CoA, ils constatent ce même effet bénéfique sur les mitochondries et laproduction d'énergie. Les cellules du cerveau sont protégées contre les changements moléculaires normaux associés au vieillissement.

On savait déjà que la fonction des mitochondries est affectée par le vieillissement et de manière dramatique dans la maladie d'Alzheimer. CMS121 et J147 apportent donc l’espoir de pouvoir inverser le vieillissement des cellules du cerveau, mais peut-être aussi d’autres organes ?

[slimlastforskolins]

Alzheimer's drug candidates reverse broader aging, study shows -- ScienceDaily

Alzheimer’s drug candidates reverse broader aging, study shows — ScienceDaily

In mouse models of Alzheimer’s disease, the investigational drug candidates known as CMS121 and J147 improve memory and slow the degeneration of brain cells. Now, Salk researchers have shown how these compounds can also slow aging in healthy older mice, blocking the damage to brain cells that normally occurs during aging and restoring the levels of specific molecules to those seen in younger…

[neurosciencenews]

Alzheimer's Drug Turns Back Clock in Powerhouse of Cell

The experimental drug J147 is something of a modern elixir of life; it's been shown to treat Alzheimer's disease and reverse aging in mice and is almost ready for clinical trials in humans. Now, Salk scientists have solved the puzzle of what, exactly, J147 does.

The research is in Aging Cell. (full access paywall)

[ruggerorespigo]

Alzheimer's drug candidates reverse broader aging, study shows

In mouse models of Alzheimer's disease, the investigational drug candidates known as CMS121 and J147 improve memory and slow the degeneration of brain cells. Now, researchers have shown how these compounds can also slow aging in healthy older mice, blocking the damage to brain cells that normally occurs during aging and restoring the levels of specific molecules to those seen in younger brains. Latest Science News -- ScienceDaily https://www.sciencedaily.com/releases/2019/12/191210134028.htm